Galectin Therapeutics (GALT) Tops Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to Galectin Therapeutics (GALT) Tops Q3 EPS by 10c

Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program

November 10, 2014 8:00 AM EST

NORCROSS, Ga., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. The Company also provided an update on its development program.

According to Peter Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics, "In the past... More